Last reviewed · How we verify

Ketamine and Magnesium Sulfate

Ain Shams University · FDA-approved active Small molecule

Ketamine acts as an NMDA receptor antagonist while magnesium sulfate enhances NMDA receptor blockade and provides neuroprotection, together reducing pain and providing anesthesia.

Ketamine acts as an NMDA receptor antagonist while magnesium sulfate enhances NMDA receptor blockade and provides neuroprotection, together reducing pain and providing anesthesia. Used for Anesthesia induction and maintenance, Acute pain management, Perioperative analgesia.

At a glance

Generic nameKetamine and Magnesium Sulfate
SponsorAin Shams University
Drug classNMDA receptor antagonist combination
TargetNMDA receptor
ModalitySmall molecule
Therapeutic areaAnesthesia, Pain Management
PhaseFDA-approved

Mechanism of action

Ketamine is a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, blocking glutamate-mediated excitatory neurotransmission and producing dissociative anesthesia and analgesia. Magnesium sulfate potentiates this effect by acting as a natural NMDA receptor antagonist and provides additional neuroprotective and anti-inflammatory benefits. This combination is used to enhance anesthetic and analgesic efficacy while potentially reducing required ketamine doses.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: